Arena Pharmaceuticals, Inc.

We are a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors (GPCRs) to address unmet medical needs. Our internally discovered drug for chronic weight management, BELVIQ ® (lorcaserin HCl), was approved by the FDA for marketing in the United States to adults who are overweight with a comorbidity or obese, and was made available to patients by our collaborator, Eisai, by prescription in June 2013. In February 2015, BELVIQ was also approved for weight management in South Korea and will be marketed by our collaborator, Ildong. We intend to explore, with our collaborators or independently, BELVIQ’s therapeutic potential in combination with other drugs, for other indications, and using different formulations. We also intend to utilize our GPCR focus and expertise to advance other of our internally discovered compounds and drug candidates.